Table 1.
Demographics and clinical parameters of our patient population. See also Table S1 and Figure S1.
| Parameter | Total (%) |
|---|---|
|
| |
| Total number | 117 |
|
| |
| Median age (range), years | 60 (17 – 84) |
|
| |
| Gender | |
| Male | 61 (52) |
| Female | 56 (48) |
|
| |
| Race | |
| Caucasian | 97 (83) |
| Black | 6 (5) |
| Asian | 12 (10) |
| Data missing | 2 (2) |
|
| |
| Ethnicity | |
| Hispanic | 9 (8) |
| Non-Hispanic | 94 (80) |
| Data missing | 14 (12) |
|
| |
| Masaoka stage | |
| I | 36 (31) |
| IIA | 39 (33) |
| IIB | 19 (16) |
| III | 15 (13) |
| IVA | 1 (1) |
| IVB | 5 (4) |
| Data missing | 2 (2) |
|
| |
| Histologic subgroup: | |
| Thymoma (total 105) | |
| Type A | 10 (9) |
| Type AB | 48 (41) |
| Type B1 | 12 (10) |
| Type B2 | 25 (21) |
| Type B3 | 10 (9) |
| Thymic carcinoma (TC) (total 10) | 4 (3) |
| Squamous cell carcinoma | 4 (3) |
| Undifferentiated carcinoma | 1 (1) |
| Large-cell neuroendocrine carcinoma | 1 (1) |
| Thymic carcinoma, NOS | |
| Micronodular Thymoma (MNT) | 2(2) |
|
| |
| Underwent surgery | |
| Median sternotomy | 72 (61) |
| Clamshell sternotomy | 1 (1) |
| Lateral thoracotomy | 22 (19) |
| Video-assisted thoracoscopic surgery (VATS) | 14 (12) |
| Type of surgery not-specified | 8 (7) |
|
| |
| Extent of surgical resection | |
| R0 (no residual tumor) | 97 (83) |
| R1 (microscopic residual tumor) | 9 (8) |
| R2 (macroscopic residual tumor) | 4 (3) |
| RX (presence of residual tumor cannot be assessed) | 2 (2) |
| Data missing | 5 (4) |
|
| |
| Adjuvant radiation therapy | 39 (33) |
|
| |
| Adjuvant systemic therapy (total 14) | |
| Platinum- and/or anthracycline-containing combination | 6 (43) |
| Other systemic therapy | 4 (29) |
| Targeted therapy | 2 (14) |
| Data missing | 2 (14) |
|
| |
| Recurrence of thymic tumor (total 10) | |
| Locoregional recurrence | 5 (50) |
| Locoregional recurrence and distant metastasis | 3 (30) |
| Distant metastasis | 2 (202) |
|
| |
| Autoimmune disease (total 39)* | |
| Myasthenia gravis only | 32 (82) |
| Non-myasthenia gravis autoimmune disease only | 7 (18) |
| Data missing** | 6 (5) |
|
| |
| Onset of myasthenia gravis (total 32) | |
| Myasthenia gravis diagnosed prior to thymoma | 20 (62.5) |
| Myasthenia gravis and thymoma diagnosed simultaneously | 7 (22) |
| Myasthenia gravis diagnosed after thymoma | 4 (12.5) |
| Data not available | 1 (3) |
|
| |
| Secondary malignancy (total 22) | |
| Diagnosed after thymic tumor | 10 (45) |
| Diagnosed prior to thymic tumor | 9 (41) |
| Diagnosed synchronously | 3 (14) |
*
One patient with type AB thymoma had acetylcholine receptor antibodies in serum but no clinical evidence for myasthenia gravis. This case has not been included among patients with autoimmune disease.
**
Data on both MG and other autoimmune disease is not available in 1 case and data on non-MG autoimmune disease alone is not available in 5 cases; these represent 5% of 117 cases.